|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Career Definitions
Labor Market Reports
Education & Training
Regions
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Introgen Therapeutics, Inc. (INGN) Appoints James E. Rothman, Ph.D., to Board of Directors
8/12/2008
AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, today announced the appointment of James E. Rothman, Ph.D., to the Company’s board of directors. In September 2008, Dr. Rothman will relocate his laboratory from Columbia University to Yale University where he will serve as the Wallace professor of biomedical sciences, chairman of the Department of Cell Biology and founder of the Yale University Center for High-Throughput Cell Biology.
|
|
|
|
|
|
|
|
|
|
|
|